Topical corticosteroids: experience with mometasone furoate.
Peets
E A
EA
Schering-Plough Corporation, Kenilworth, N.J., USA.
D000279:Administration, Cutaneous; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000818:Animals; D001284:Atrophy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D018849:Controlled Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy*; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D017453:Dermatitis, Irritant / Q000188:drug therapy*; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000209:etiology; D004353:Drug Evaluation, Preclinical; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007223:Infant; D007801:Langerhans Cells / Q000187:drug effects; D008297:Male; D051379:Mice; D008875:Middle Aged; D000068656:Mometasone Furoate; D015337:Multicenter Studies as Topic; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011244:Pregnadienediols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012867:Skin / Q000187:drug effects / Q000473:pathology
D000305:Adrenal Cortex Hormones; D016207:Cytokines; D011244:Pregnadienediols; D000068656:Mometasone Furoate